A
Alzinova AB
STO:ALZ
Alzinova AB
STO:ALZ
Price:
0.454
SEK
-5.42%
Market Closed
Market Cap:
kr70.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Alzinova AB
Accounts Receivables
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Alzinova AB
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alzinova AB
STO:ALZ
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Accounts Receivables
kr222.3m
|
CAGR 3-Years
41%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Accounts Receivables
kr665m
|
CAGR 3-Years
14%
|
CAGR 5-Years
25%
|
CAGR 10-Years
21%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Accounts Receivables
kr7.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
32%
|
|
|
BioArctic AB
STO:BIOA B
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Alzinova AB
Glance View
Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2015-11-25. The firm is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The firm focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
ALZ
Intrinsic Value
0.104
SEK
Overvaluation 77%
A
